Skip to content

Mismatch-Guided Endovascular Treatment to Rescue Ischemic Brain Tissue for Acute Ischemic Stroke: a Multicenter, Open-Label, Randomized Controlled Trial (MERIT)

Mismatch-Guided Endovascular Treatment to Rescue Ischemic Brain Tissue for Acute Ischemic Stroke: a Multicenter, Open-Label, Randomized Controlled Trial (MERIT)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047505
Enrollment
Unknown
Registered
2021-06-20
Start date
2021-06-30
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior circulation large vessel occlusion

Interventions

Group A:Endovascular thrombectomy
Group B:Standard medical therapy

Sponsors

Zhongshan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Clinical inclusion criteria 1. Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke; 2. Aged 18 to 85 years old; 3. Baseline NIHSS >= 6; 4. Mechanical thrombectomy can be initiated (femoral puncture) within 6–24 h of stroke onset. Stroke onset is defined as the time of the last known normal; 5. Pre-stroke mRS =15 mL).

Exclusion criteria

Exclusion criteria: Clinical exclusion criteria 1. Serious heart/renal/liver dysfunction; 2. Pregnancy; 3. Known allergy to iodine; 4. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, and recent oral anticoagulant therapy with INR > 3'; 5. Baseline platelet count 22.2 mmol/L; 7. Severe sustained hypertension (systolic blood pressure >185 mmHg or diastolic blood pressure > 110 mmHg); 8. Treated with tPA at > 4.5 h after time last known well; 9. Treated with tPA at 3–4.5 h after last known well and any of the following: aged > 80 years, current anticoagulant use, history of diabetes and prior stroke, NIHSS score >25; 10. Anticipated life expectancy 10 mm), arteriovenous malformation, moyamoya disease, or intracranial tumor (except asymptomatic meningioma); 3. Significant mass effect with midline shift as confirmed on CT or MRI; 4. Occlusion in multiple vascular territories (bilateral anterior circulation or anterior circulation/vertebrobasilar system) as confirmed on CTA or MRA; 5. Intracranial stents are implanted in the same vascular territory that precludes the safe deployment or removal of the thrombectomy device.

Design outcomes

Secondary

MeasureTime frame
NIH Stroke Scale, NIHSS;Barthel;

Primary

MeasureTime frame
mRS;

Countries

China

Contacts

Public ContactWang Xin

Zhongshan Hospital of Fudan University

wang.xin@zs-hospital.sh.cn+86 13501909896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026